Perpendicular magnetic anisotropy at Fe/Au(111) interface studied by M\"{o}ssbauer, x-ray absorption, and photoemission spectroscopies

The origin of the interfacial perpendicular magnetic anisotropy (PMA) induced in the ultrathin Fe layer on the Au(111) surface was examined using synchrotron-radiation-based M\"{o}ssbauer spectroscopy (MS), X-ray magnetic circular dichroism (XMCD), and angle-resolved photoemission spectroscopy (ARPES). To probe the detailed interfacial electronic structure of orbital hybridization between the Fe 3$d$ and Au 6$p$ bands, we detected the interfacial proximity effect, which modulates the valence-band electronic structure of Fe, resulting in PMA. MS and XMCD measurements were used to detect the interfacial magnetic structure and anisotropy in orbital magnetic moments, respectively. $In$-$situ$ ARPES also confirms the initial growth of Fe on large spin-orbit coupled surface Shockley states under Au(111) modulated electronic states in the vicinity of the Fermi level. This suggests that PMA in the Fe/Au(111) interface originates from the cooperation effects among the spin, orbital magnetic moments in Fe, and large spin-orbit coupling in Au. These findings pave the way to develop interfacial PMA using $p$-$d$ hybridization with a large spin-orbit interaction

The Mikabu and Chichibu belts in the Iya-gawa area, Tokushima Prefecture, Shikoku, SW Japan : An integrated research of geology and geomorphology

The Mikabu and Chichibu belts in the Iya-gawa area are studied with respect to their composition, boundaries and the relation with landslides. The Kyobashira-Sugeoi Fault bound the Mikabu Greenstone Belt from the Sambagawa Belt. The Kubo Greenstone body, a part of the Mikabu Greenstone, distributes as an axial part of antiform in the southern margin of the Sambagawa Belt. The Mikabu Greenstone of the area is composed of tholeiitic and alkaline rocks. The Mikabu Greenstone thrust to the south with the Okoyatoko-Nagoro Fault upon the Jurassic accretionary complex of the North Chichibu Belt. Even the phillite generally dipping towards the north in the northern part of the North Chichibu Belt, the oceanic-plate successions of chert-mudstone sequences are stratigraphically upper towards the south. The radiolarian age, estimated at the lithological transition from chert to mudstone in the oceanic-plate sequences, is Early Jurassic. The landslides concentrate in the areas of the Mikabu Greenstone and valley walls along the Iya-gawa River. The linear depressions and ponds, arrange on the mountain ridge between the Miune and Tengu-Zuka along the southern border of the Mikabu Greenstone, are regarded as a sign of large-scale collapse by long-period gravitational mass rock deformation of the mountain body. The weathered zone of the Mikabu Greenstone often includes swelling clay that causes landslides in the area

血漿ADAMTSは肝硬変患者の予後をChild-PughスコアやMELDスコアと同様に生存率を予測できる可能性がある

Aim:  Decreased plasma ADAMTS13 activity (ADAMTS13:AC) results in accumulation of unusually large von Willebrand factor multimers and platelet thrombi formation. Our aim was to evaluate whether ADAMTS13:AC is a prognostic marker in patients with liver cirrhosis. Methods:  Plasma ADAMTS13:AC and its related parameters were examined in 108 cirrhotic patients. Results:  ADAMTS13:AC decreased as the severity of liver disease increased (means: controls 100%, Child A-cirrhotics 79%, Child B-cirrhotics 63%, and Child C-cirrhotics 31%). ADAMTS13:AC markedly decreased in the cirrhotics with hepatorenal syndrome, refractory ascites and hepatic encephalopathy. The cumulative survival time was the shortest (median: 4.5 months) in the cirrhotics with severe to moderate ADAMTS13:AC deficiency (50%). In contrast, based on the Child-Turcotte-Pugh (CTP) score, Child C-cirrhotics had the worst survival, but the survival probabilities did not differ between Child A and B cirrhotics. Based on the Model for End-Stage Liver Disease (MELD) score, the survival was the worst for the cirrhotics in the fourth quartile, but it was not different among cirrhotics in the first three quartiles. Cox proportional-hazards regression analysis showed that ADAMTS13:AC and serum albumin were independent factors affecting the survival. Conclusions:  ADAMTS13:AC concomitantly decreases as the functional liver capacity decreases. This activity may be a useful prognostic marker that is equal or superior to the CTP score and the MELD score to predict not only the short-term prognosis but also the long-term survival of the cirrhotic patients.博士（医学）・甲613号・平成26年3月17

Superior vena cava syndrome causedby adult T-cell leukemia/lymphoma: a case report

A 74-year-old man with a smoking history was admitted for back and right arm pain. On examination, swelling of the face and arms were noted, and computed tomographic imaging of the chest demonstrated a bulky (10.0 x 7.2 cm) tumor in the right upper mediastinum. The lesion compressed the superior vena cava (SVC). Despite treatment, the patient died 5 months after the first admission. On autopsy, he was diagnosed that SVC syndrome caused by adult T-cell leukemia/lymphoma (ATL). ATL usually runs an aggressive course with multiple organs involving lymph nodes, liver, spleen, skin, lung, peripheral blood and bone marrow. Although it is extremely rare, SVC syndrome can appear as the earliest symptom of ATL

Secondary EML4?ALK-positive Lung Adenocarcinoma in a Patient Previously Treated for Acute Lymphoblastic Leukemia in Childhood: A Case Reportated for Acute Lymphoblastic Leukemia in Childhood: A Case Report

It is widely recognized that the risk of secondary neoplasms increases as childhood cancer survivors progress through adulthood. These are mainly hematological malignancies, and recurrent chromosome translocations are commonly detected in such cases. On the other hand, while secondary epithelial malignancies have sometimes been reported, chromosome translocations in these epithelial malignancies have not. A 33-year-old man who had been diagnosed with acute lymphoblastic leukemia and treated with chemotherapy almost 20 years earlier was diagnosed with lung adenocarcinoma. After chromosomal rearrangement of echinoderm microtubule- associated protein-like 4 gene and the anaplastic lymphoma kinase gene was detected in this adenocarcinoma, he responded to treatment with crizotinib. It was therefore concluded that this echinoderm microtubule-associated protein-like 4 gene-anaplastic lymphoma kinase gene-positive lung adenocarcinoma was a secondary epithelial malignancy

Porous Plug Phase Separator and Superfluid Film Flow Suppression System for the Soft X-Ray Spectrometer Onboard Hitomi

When using superfluid helium in low gravity environments, porous plug phase separators are commonly used to vent boiloff gas while confining the bulk liquid to the tank. Invariably, there is a flow of superfluid film from the perimeter of the porous plug down the vent line. For the Soft X-ray Spectrometer onboard ASTRO-H (Hitomi), its approximately 30-liter helium supply has a lifetime requirement of more than 3 years. A nominal vent rate is estimated as ~ 30 ug/s, equivalent to ~ 0.7 mW heat load. It is therefore critical to suppress any film flow whose evaporation would not provide direct cooling of the remaining liquid helium. That is, the porous plug vent system must be designed to both minimize film flow and to ensure maximum extraction of latent heat from the film. The design goal for Hitomi is to reduce the film flow losses to <2 ug/s, corresponding to a loss of cooling capacity of <40 uW. The design adopts the same general design as implemented for Astro-E and E2, using a vent system composed of a porous plug, combined with an orifice, a heat exchanger, and knife-edge devices. In this paper, design, on-ground testing results and in-orbit performance are described

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

Background: We conducted a phase II trial of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations and evaluated the relationship between plasma concentration and efficacy of erlotinib. Methods: Patients who were previously treated but naive to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), with advanced NSCLC harboring EGFR mutations, were enrolled. Erlotinib was given at 150 mg once daily until disease progression. The primary end point was objective response rate (ORR). Plasma trough levels of erlotinib were measured on Days 2 (D2) and 8 (D8) by high-performance liquid chromatography. Results: In total, 29 patients were enrolled from September 2008 to January 2011. ORR was 61.5 % (95 % confidence interval [CI] 40.57-79.8) of 26 assessable patients. The median progression-free survival (PFS) and overall survival (OS) were 6.3 months and 16.9 months, respectively. Skin rash was observed in 24 patients, mostly at grade 1 or 2. Grade 2 pneumonitis was observed in one patient. We collected blood samples from 16 patients. The median PFS of the high and low D8/D2 ratio group was 11.2 months and 5.7 months, respectively (p = 0.044, hazard ratio = 0.301, 95 % CI 0.094-0.968). Conclusion: Erlotinib showed an ORR comparable to that seen in previous studies for patients with NSCLC harboring EGFR mutations, although response, the primary end point, did not reach the predetermined threshold level. The D8/D2 ratio of erlotinib plasma trough levels might be a predictive factor for PFS

Cooling system for the soft X-ray spectrometer onboard Astro-H

金沢大学理工研究域数物科学系The Soft X-ray Spectrometer (SXS) is a cryogenic high resolution X-ray spectrometer onboard the X-ray astronomy satellite Astro-H which will be launched in 2014. The detector array is cooled down to 50 mK using an adiabatic demagnetization refrigerator (ADR). The cooling chain from the room temperature to the ADR heat-sink is composed of superfluid liquid He, a Joule-Thomson cryocooler, and double-stage Stirling cryocoolers. It is designed to keep 30 l of liquid He for more than 5 years in the normal case, and longer than 3 years even if one of the cryocoolers fails. Cryogen-free operation is also possible in the normal case. It is fully redundant from the room temperature to the ADR heat-sink. © 2010 Elsevier Ltd

A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer

Background: Amrubicin is active in the treatment of extensive-disease small cell lung cancer (ED-SCLC), and carboplatin is an analogue of cisplatin with less non-hematological toxicity. Purpose: The purpose of this study was to determine the efficacy and toxicity of amrubicin and carboplatin combination chemotherapy for previously untreated patients with ED-SCLC. Patients and methods: Eligibility criteria were chemotherapy-naive ED-SCLC patients, performance status 0-1, age ?75, and adequate hematological, hepatic and renal function. Based on the phase I study, the patients received amrubicin 35 mg/m2 i.v. infusion on days 1, 2, and 3, and carboplatin AUC 5 i.v. infusion on day 1. Four cycles of chemotherapy were repeated every 3 weeks. Results: Thirty-five patients were enrolled, and 34 patients were eligible and assessable for response, toxicity, and survival. Patients\u27 characteristics were as follows: male/female = 26/8; performance status 0/1 = 4/30; median age (range) = 64 (41-75); stage IV = 34. Evaluation of responses was 6 complete response, 21 partial response, and 7 stable disease (response rate 79.4 %, 95 % CI 63.6-88.5 %). Grade 3 and 4 leukopenia, neutropenia, and thrombocytopenia occurred in 59, 82, and 26 %, respectively. There were no treatment-related deaths or pneumonitis. Three patients experienced hypotension as an amrubicin infusion reaction. The median progression-free survival time was 6.5 months. The median overall survival time and 1-, 2-, and 3-year survival rates were 15.6 months, and 63, 28, and 7 %, respectively. Conclusions: Amrubicin and carboplatin were effective and tolerable as chemotherapy for previously untreated patients with ED-SCLC. Further investigation of amrubicin and carboplatin is warranted